Get started
Author

Katrine B. Melhus

Targeted cancer therapy with a novel low-dose rate α-emitting radioimmunoconjugate
2007 · Jostein Dahle, Jørgen Borrebæk, et al. · Blood · 80
PDF
Initial evaluation of 227Th-p-benzyl-DOTA-rituximab for low-dose rate α-particle radioimmunotherapy
2006 · Jostein Dahle, Jørgen Borrebæk, et al. · Nuclear Medicine and Biology · 57
Preparation of TH 227 -Labeled Radioimmunoconjugates, Assessment of Serum Stability and Antigen Binding Ability
2007 · Roy H. Larsen, Jorgen Borrebaek, et al. · Cancer Biotherapy and Radiopharmaceuticals · 49
Evaluating antigen targeting and anti-tumor activity of a new anti-CD37 radioimmunoconjugate against non-Hodgkin's lymphoma.
2013 · Jostein Dahle, Ada H V Repetto-Llamazares, et al. · PubMed · 44
In Vitro Cytotoxicity of Low-Dose-Rate Radioimmunotherapy by the Alpha-Emitting Radioimmunoconjugate Thorium-227–DOTA–Rituximab
2009 · Jostein Dahle, Cecilie Krogh, et al. · International Journal of Radiation Oncology*Biology*Physics · 22
Evaluation of the Binding of Radiolabeled Rituximab to CD20-Positive Lymphoma Cells: An In Vitro Feasibility Study Concerning Low-Dose-Rate Radioimmunotherapy with the α -Emitter 227 Th
2007 · Katrine B. Melhus, Roy H. Larsen, et al. · Cancer Biotherapy and Radiopharmaceuticals · 20
The Dual Cell Cycle Kinase Inhibitor JNJ-7706621 Reverses Resistance to CD37-Targeted Radioimmunotherapy in Activated B Cell Like Diffuse Large B Cell Lymphoma Cell Lines
2019 · Gro Elise Rødland, Katrine Melhus, et al. · Frontiers in Oncology · 18
PDF
Comprehensive analysis of 177 Lu ‐lilotomab satetraxetan in lymphoma cell lines: Implications for precision radioimmunotherapy and combination schemes
2025 · Sebastian Patzke, Sebastian Patzke, et al. · British Journal of Haematology · 2
PDF
A Higher Amount of Lilotomab Pre-dosing Increases the Activity-adjusted Auc and Has a Protective Effect Against Myelosuppression of Lutetium (177lu)-lilotomab Satetraxetan in Indolent Nhl Patients
2017 · Arne Kolstad, Ulf Madsbu, et al. · Research Explorer (The University of Manchester) · 2
A one-step method for determining the maximum number of bound antibodies, and the affinity and association rate constants for antibody binding
2007 · Jostein Dahle, Cecilie Krogh, et al. · Nuclear Medicine Communications · 2
The Dual Cell Cycle Kinase Inhibitor JNJ-7706621 Reverses Resistance to CD37 Targeted Radioimmunotherapy in Activated B Cell like Diffuse Large B Cell Lymphoma Cell Lines
2019 · Gro Elise Rødland, Katrine Melhus, et al. · Blood · 1
Re-Evaluation of CD37 As Target for Radioimmunotherapy of Non-Hodgkin Lymphoma,
2011 · Jostein Dahle, Ada Repetto, et al. · Blood · 1
Comprehensive Analysis of 177Lu-lilotomab Satetraxetan in Lymphoma Cell Lines: Implications for Precision Radioimmunotherapy and Combination Schemes
2025 · Sebastian Patzke, Luciano Cascione, et al. · Research Square
PDF
Cell Cycle Kinase Inhibitors Potentiate the Effect of 177lu-Lilotomab Satetraxetan in Treatment of Aggressive Diffuse Large B-Cell Lymphoma Cell Lines
2018 · Gro Elise Rødland, Katrine Melhus, et al. · Blood
Works count: 14
Citation count: 298
H-index: 7
I10-index: 7
Year
Topic
Type